Partner Headlines - BMRN

  1. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  2. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  3. Top Trending Tickers On StockTwits For February 18

    Benzinga
  4. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  5. You Can No Longer Ignore Biotech

    GuruFocus
  6. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  7. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  8. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  9. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  10. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  11. Benzinga's Top #PreMarket Gainers

    Benzinga
  12. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  13. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  14. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  15. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  16. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  17. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  18. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  19. Roche

    IBD
  20. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  21. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  22. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  23. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  24. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  25. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  26. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  27. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  28. Benzinga's Volume Movers

    Benzinga
  29. Benzinga's Top Pre-Market Gainers

    Benzinga
  30. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  31. Benzinga's Top Pre-Market Gainers

    Benzinga
  32. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  33. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  34. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  35. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  36. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  37. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  38. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  39. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  40. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  41. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  42. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  43. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  44. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  45. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  46. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  47. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  48. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  49. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  50. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  51. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  52. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  53. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  54. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  55. BioMarin soars on drug data

    IBD
  56. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  57. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  58. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
  59. Stocks Hitting 52-Week Highs

    Benzinga
  60. BioMarin Stock Soars On Positive Drug Data

    IBD
  61. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga
  62. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  63. BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q)

    GuruFocus
  64. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  65. UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical ...

    Benzinga
  66. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  67. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  68. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  69. Health Care Sector Wrap

    FoxBusiness
  70. Benzinga's Top Downgrades

    Benzinga
  71. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  72. BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ ...

    Benzinga
  73. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  74. BioMarin Pharmaceutical, Health Net Among Stocks Up on High Volume ...

    FoxBusiness
  75. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  76. Amylin Pharmaceuticals, Constellation Brands Among Stocks Setting ...

    FoxBusiness
  77. Analyst Initiations: BMRN, FB, and MDVN

    SchaeffersResearch
  78. Benzinga's Top Pre-Market Gainers

    Benzinga
  79. From Earlier: Wedbush Reiterates BioMarin Pharmaceuticals Neutral, ...

    Benzinga
  80. Benzinga's Morning Initiation Summary for June 1, 2012

    Benzinga
  81. BioMarin Pharmaceutical (BMRN) Loses 7.2% After Pricing Offering ...

    MarketIntelligenceCenter
  82. BioMarin Announces Pricing of Public Offering of Common Stock; ...

    Benzinga
  83. UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

    Benzinga
  84. BioMarin Pharmaceutical (BMRN) Loses 1.3% as Volatility Continues

    MarketIntelligenceCenter
  85. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  86. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  87. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  88. BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper ...

    GuruFocus
  89. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  90. Upgrades & Downgrades: YHOO, BMRN, HGSI, DNDN, and TSLA

    SchaeffersResearch
  91. Just What The Doctor Ordered: 4 ETFs For Biotech M&A

    Benzinga
  92. BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper ...

    GuruFocus
  93. Stocks at New Highs: BioMarin Pharmaceutical and Seattle Genetics

    SchaeffersResearch
  94. Call Volume Spikes on BioMarin Pharmaceutical

    SchaeffersResearch
Trading Center